When the Science Center closed out its most recent Capital Readiness Program cohort, Chirag Goel, Principal at Chicago-based Propellant Ventures echoed a theme we hear from investors every cohort: the strongest fundraise you can achieve isn't your next round. It's revenue. That’s precisely the point.

What does it take to move cardiovascular innovation from bench to bedside? Dr. Kevin Baumlin, chief medical affairs officer of the Science Center and former professor and chair of Emergency Medicine at Pennsylvania Hospital, moderated a cross-sector discussion between cardiologist Dr. Rajan Jain, associate professor of Medicine at the University

We’ve all heard the adage that an ounce of prevention is worth a pound of cure. Yet, patient adherence is a complex issue with numerous factors that can make it challenging to follow clinician recommendations.

In 2023, the FDA approved the first cell-based gene therapies to treat sickle cell disease, a lifelong illness that shaves 20–25 years off average life expectancy. However, the process of collecting and genetically modifying a patient’s own blood cells is intensive, with treatments costing as much as $3.3 million. Despite